Ge Health Care Technologies Inc. - Understand $gehc stock

$GEHC Market Cap: $37.93 Billion

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$19.56B

TTM

Gross Margin

41.33%

TTM

Net Earnings

$1.675B

TTM

Current Assets

$10.64B

Q3 2024

Current Liabilities

$8.670B

Q3 2024

Current Ratio

122.7%

Q3 2024

Total Assets

$33.86B

Q3 2024

Total Liabilities

$25.34B

Q3 2024

Book Value

$8.512B

Q3 2024

Cash

$3.550B

Q3 2024

P/E

22.64

Nov 29, 2024 EST

Free Cash Flow

$1.695B

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2023	2022	2021	2020	2019
Revenue	$19.55B	$18.34B	$17.59B	$17.16B	$16.63B
YoY Change	6.6%	4.3%	2.45%	3.19%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2023	2022	2021	2020	2019
Revenue	$19.55B	$18.34B	$17.59B	$17.16B	$16.63B
Cost Of Revenue	$11.63B	$11.16B	$10.41B	$10.40B	$10.09B
Gross Profit	$7.922B	$7.179B	$7.174B	$6.767B	$6.548B
Gross Profit Margin	40.52%	39.14%	40.8%	39.43%	39.37%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2023	2022	2021	2020	2019
Selling, General & Admin	$4.282B	$3.631B	$3.563B	$3.237B	$3.591B
YoY Change	17.93%	1.91%	10.07%	-9.86%
% of Gross Profit	54.05%	50.58%	49.67%	47.84%	54.84%
Research & Development	$1.205B	$1.026B	$816.0M	$810.0M	$833.0M
YoY Change	17.45%	25.74%	0.74%	-2.76%
% of Gross Profit	15.21%	14.29%	11.37%	11.97%	12.72%
Depreciation & Amortization	$248.0M	$633.0M	$625.0M	$630.0M	$659.0M
YoY Change	-60.82%	1.28%	-0.79%	-4.4%
% of Gross Profit	3.13%	8.82%	8.71%	9.31%	10.06%
Operating Expenses	$5.487B	$4.657B	$4.379B	$4.047B	$4.424B
YoY Change	17.82%	6.35%	8.2%	-8.52%
Operating Profit	$2.435B	$2.522B	$2.795B	$2.720B	$2.124B
YoY Change	-3.45%	-9.77%	2.76%	28.06%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2023	2022	2021	2020	2019
Interest Expense	-$505.0M	-$81.00M	-$101.0M	-$122.0M	-$142.0M
YoY Change	523.46%	-19.8%	-17.21%	-14.08%
% of Operating Profit	-20.74%	-3.21%	-3.61%	-4.49%	-6.69%
Other Income/Expense, Net	$86.00M	$71.00M	$181.0M	$112.0M	$109.0M
YoY Change	21.13%	-60.77%	61.61%	2.75%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2023	2022	2021	2020	2019
Pretax Income	$2.361B	$2.512B	$2.875B	$2.710B	$2.091B
YoY Change	-6.01%	-12.63%	6.09%	29.6%
Income Tax	$743.0M	$563.0M	$600.0M	$652.0M	$410.0M
% Of Pretax Income	31.47%	22.41%	20.87%	24.06%	19.61%
Net Earnings	$1.568B	$1.916B	$2.247B	$13.85B	$1.524B
YoY Change	-18.16%	-14.73%	-83.77%	808.53%
Net Earnings / Revenue	8.02%	10.45%	12.78%	80.67%	9.16%
Basic Earnings Per Share	$3.05	$4.22	$4.95
Diluted Earnings Per Share	$3.03	$4.22	$4.94	$30.45	$3.35

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2023	2022	2021	2020
Cash & Short-Term Investments	$2.504B	$1.445B	$556.0M	$1.007B
YoY Change	73.29%	159.89%	-44.79%
Cash & Equivalents	$2.504B	$1.445B	$556.0M	$1.007B
Short-Term Investments
Other Short-Term Assets	$389.0M	$417.0M	$437.0M	$413.0M
YoY Change	-6.71%	-4.58%	5.81%
Inventory	$1.960B	$2.155B	$1.946B	$1.594B
Prepaid Expenses
Receivables	$4.525B	$4.284B	$4.029B	$2.705B
Other Receivables	$32.00M	$17.00M	$32.00M	$177.0M
Total Short-Term Assets	$9.410B	$8.318B	$7.000B	$5.896B
YoY Change	13.13%	18.83%	18.72%
Property, Plant & Equipment	$2.500B	$2.314B	$2.235B	$2.202B
YoY Change	8.04%	3.53%	1.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.231B	$2.429B	$2.196B	$2.524B
YoY Change	156.53%	10.61%	-13.0%
Total Long-Term Assets	$23.04B	$19.22B	$19.31B	$18.33B
YoY Change	19.89%	-0.45%	5.32%
Total Assets	$32.45B	$27.54B	$26.31B	$24.23B
YoY Change
Accounts Payable	$2.947B	$2.944B	$2.540B	$2.162B
YoY Change	0.1%	15.91%	17.48%
Accrued Expenses	$110.0M	$104.0M	$104.0M	$128.0M
YoY Change	5.77%	0.0%	-18.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$8.000M	$6.000M	$4.000M
YoY Change	-100.0%	33.33%	50.0%
Long-Term Debt Due	$1.006B	$7.000M	$6.000M	$4.000M
YoY Change	14271.43%	16.67%	50.0%
Total Short-Term Liabilities	$8.981B	$7.191B	$6.761B	$6.524B
YoY Change	24.89%	6.36%	3.63%
Long-Term Debt	$8.436B	$8.234B	$31.00M	$31.00M
YoY Change	2.45%	26461.29%	0.0%
Other Long-Term Liabilities	$7.659B	$2.152B	$2.235B	$2.240B
YoY Change	255.9%	-3.71%	-0.22%
Total Long-Term Liabilities	$16.10B	$10.39B	$2.266B	$2.271B
YoY Change	54.97%	358.34%	-0.22%
Total Liabilities	$25.32B	$18.18B	$9.653B	$9.501B
YoY Change	39.26%	88.36%	1.6%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2023	2022	2021
Basic Shares Outstanding	455.0M shares	454.0M shares	454.0M shares
Diluted Shares Outstanding	458.0M shares	454.0M shares	454.0M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $37.925 Billion

About GE HealthCare Technologies Inc.

GE Healthcare Technologies, Inc. engages in the development and manufacturing of medical technology, pharmaceutical diagnostics, and digital solutions. The company is headquartered in Chicago, Illinois and currently employs 51,000 full-time employees. The company went IPO on 2022-12-15. The firm provides integrated solutions, services, and data analytics. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. The segment also includes the clinical artificial intelligence (AI) software business. Its PCS segment portfolio consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment consists of two business lines: contrast media and molecular imaging.

Industry: X-Ray Apparatus & Tubes & Related Irradiation Apparatus Peers: ABBOTT LABORATORIES BAXTER INTERNATIONAL INC BECTON DICKINSON & CO BOSTON SCIENTIFIC CORP Edwards Lifesciences Corp DEXCOM INC IDEXX LABORATORIES INC /DE INSULET CORP RESMED INC ZIMMER BIOMET HOLDINGS, INC.